PDLI insider filings
PDL BIOPHARMA, INC. — 25 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-02-03. Screen PDLI transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for PDLI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — PDL BIOPHARMA, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-02-03 | 4 | Silver Point Capital L.P. — 10% owner O'Shea Robert J — 10% owner MULE EDWARD A — 10% owner | Purchase (P): 187,061 @ $2.05 | EDGAR |
| 2021-01-04 | 4 | Silver Point Capital L.P. — 10% owner O'Shea Robert J — 10% owner MULE EDWARD A — 10% owner | Purchase (P): 6,325,213 @ $2.50 | EDGAR |
| 2020-12-31 | 4 | GRYSKA DAVID W — Director | Sale (S): 20,000 @ $2.74 | EDGAR |
| 2020-12-29 | 4 | Silver Point Capital L.P. — 10% owner O'Shea Robert J — 10% owner MULE EDWARD A — 10% owner | Purchase (P): 128,000 @ $2.65 · Purchase (P): 235,000 @ $2.70 · Purchase (P): 268,600 @ $2.69 | EDGAR |
| 2020-12-23 | 4 | Silver Point Capital L.P. — 10% owner O'Shea Robert J — 10% owner MULE EDWARD A — 10% owner | Purchase (P): 230,000 @ $2.63 · Purchase (P): 850,000 @ $2.59 · Purchase (P): 485,000 @ $2.60 | EDGAR |
| 2020-12-22 | 4 | MCLAUGHLIN JOHN PETER — Director | Sale (S): 50,000 @ $2.62 · Sale (S): 277,934 @ $2.61 | EDGAR |
| 2020-12-18 | 4 | Silver Point Capital L.P. — 10% owner O'Shea Robert J — 10% owner MULE EDWARD A — 10% owner | Purchase (P): 1,350,000 @ $2.58 · Purchase (P): 398,000 @ $2.61 | EDGAR |
| 2020-12-17 | 4 | Monnet Dominique — President and CEO | Sale (S): 500,000 @ $2.60 | EDGAR |
| 2020-12-17 | 4 | Stone Christopher Lewis — VP, Gen. Counsel & Secretary | Sale (S): 200,000 @ $2.56 | EDGAR |
| 2020-12-17 | 4 | GRYSKA DAVID W — Director | Sale (S): 75,000 @ $2.68 | EDGAR |
| 2020-12-15 | 4 | Silver Point Capital L.P. — 10% owner O'Shea Robert J — 10% owner MULE EDWARD A — 10% owner | Purchase (P): 450,000 @ $2.45 · Purchase (P): 640,000 @ $2.62 · Purchase (P): 1,000,000 @ $2.59 | EDGAR |
| 2020-12-09 | 4 | GRYSKA DAVID W — Director | Option exercise (M): 66,050 @ $1.64 · Option exercise (M): 66,050 (derivative) @ $1.64 | EDGAR |
| 2020-12-04 | 4 | Stone Christopher Lewis — VP, Gen. Counsel & Secretary | Disposition to issuer (D): 11,544 @ $0 | EDGAR |
| 2020-12-04 | 4 | GRYSKA DAVID W — Director | Sale (S): 75,000 @ $2.52 | EDGAR |
| 2020-11-24 | 4 | O'Farrell Elizabeth G. — Director | Sale (S): 25,826 @ $2.44 | EDGAR |
| 2020-11-24 | 4 | GRYSKA DAVID W — Director | Sale (S): 50,000 @ $2.43 | EDGAR |
| 2020-11-20 | 4 | O'Farrell Elizabeth G. — Director | Sale (S): 63,291 @ $2.38 | EDGAR |
| 2020-11-20 | 4 | Bazaar Alan Lee — Director | Option exercise (M): 37,080 @ $1.71 · Tax withholding (F): 26,642 @ $2.38 · Sale (S): 33,435 @ $2.42 · Option exercise (M): 37,080 (derivative) @ $1.71 | EDGAR |
| 2020-11-20 | 4 | GRYSKA DAVID W — Director | Option exercise (M): 60,000 @ $1.64 · Option exercise (M): 60,000 (derivative) @ $1.64 | EDGAR |
| 2020-11-19 | 4 | GRYSKA DAVID W — Director | Sale (S): 100,000 @ $2.40 · Sale (S): 50,000 @ $2.39 | EDGAR |
| 2020-08-24 | 4 | Hernday Natasha — Director | Grant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63 | EDGAR |
| 2020-08-24 | 4 | O'Farrell Elizabeth G. — Director | Grant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63 | EDGAR |
| 2020-08-24 | 4 | Bazaar Alan Lee — Director | Grant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63 | EDGAR |
| 2020-08-24 | 4 | MCLAUGHLIN JOHN PETER — Director | Grant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63 | EDGAR |
| 2020-08-24 | 4 | GRYSKA DAVID W — Director | Grant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63 | EDGAR |
Recent 8-K events — PDL BIOPHARMA, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2020-12-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-12-08 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-10-07 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-10-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-09-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-09-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-09-09 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-09-01 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-08-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PDLI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs